Cargando…
Salvage Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) for T4b Esophageal Cancer After Definitive Chemoradiotherapy
BACKGROUND: Patients with esophageal cancer that invades adjacent structures (cT4b) are precluded from surgery and usually treated with definitive chemoradiotherapy (dCRT). dCRT might result in sufficient downstaging to enable a radical resection, possibly improving survival. This study aimed to a...
Autores principales: | Defize, I. L., van der Horst, S., Bülbul, M., Haj Mohammad, N., Mook, S., Meijer, G. J., Brosens, L. A. A., Ruurda, J. P., van Hillegersberg, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043929/ https://www.ncbi.nlm.nih.gov/pubmed/33341917 http://dx.doi.org/10.1245/s10434-020-09425-2 |
Ejemplares similares
-
ASO Author Reflections: Preoperative Selection of cT4b Esophageal Cancer Patients Who Benefit From a Salvage Robot-Assisted Minimally Invasive Esophagectomy (RAMIE)
por: Defize, Ingmar L., et al.
Publicado: (2020) -
Prognosis and Treatment After Diagnosis of Recurrent Esophageal Carcinoma Following Esophagectomy with Curative Intent
por: Parry, K., et al.
Publicado: (2015) -
Oncologic Long-Term Results of Robot-Assisted Minimally Invasive Thoraco-Laparoscopic Esophagectomy with Two-Field Lymphadenectomy for Esophageal Cancer
por: van der Sluis, P. C., et al.
Publicado: (2015) -
ASO Author Reflections: Safety and Feasibility of Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) with Three-Field Lymphadenectomy and Neoadjuvant Chemoradiotherapy in Patients with Resectable Esophageal Cancer and Cervical Lymph Node Metastasis
por: Weijs, T. J., et al.
Publicado: (2023) -
Risk Factors for Tumor Positive Resection Margins After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: Results From the Dutch Upper GI Cancer Audit: A Nationwide Population-Based Study
por: Defize, Ingmar L., et al.
Publicado: (2023)